Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Phase 1 Unknown 20 enrolled First Affiliated Hospital of Wenzhou Medical University Hrain Biotechnology Co., Ltd. · collab Second Affiliated Hospital of Nanchang University · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm open-label phase I study to determine the effect of CD19- CAR-T Cells infusion followed by allogeneic stem cell transplantation in safety, efficacy and engraftment potential in patients with CD19+ B-lineage leukemia and lymphoma.

Timeline

Start: 2016-10-01
Primary completion: 2020-06
Completion: 2021-09

Publications

Dong R, Jiang S, Chen Y, Ma Y, Sun L, Xing C, Zhang S, Yu K. Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell Therapy. J Interferon Cytokine Res. 2021 Dec;41(12):469-476. doi: 10.1089/jir.2021.0057.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	anti-CD19 CAR-T	Cell therapy	—	—
Background	Cyclophosphamide	Other / unclassified	500 mg/m2	—
Background	Fludarabine	Small molecule	25 mg/m2	—

Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Summary

Timeline

Publications

Drugs

Indications